Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Current Report · Items 2.02, 9.01 · 8-K

Allurion Technologies, Inc.

Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition. On January 12, 2026, Allurion Technologies, Inc. issued a press release announcing selected preliminary financial results for the quarter and year ended December 31, 2025. The full text of that press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference.…

Filed Jan 12, 2026Accepted Jan 12, 2026, 4:30 PM ESTCIK 1964979Accession 0001193125-26-010462
Share

Company context

Allurion is a pioneer in metabolically healthy weight loss. The Allurion Program is a weight-loss platform that combines the Allurion Smart Capsule, the world’s first and only swallowable, ProcedurelessTM gastric balloon for weight loss, the Allurion Virtual Care Suite, including the Allurion Mobile App for consumers and Allurion Insights for healthcare providers featuring the Iris AI Platform, and the Allurion Connected Scale. The Allurion Virtual Care Suite is also available to providers separately from the Allurion Program to help customize, monitor, and manage weight-loss therapy for patients regardless of their treatment plan. The Allurion Smart Capsule is an investigational device in the United States.

Current securities

Historical securities (4)

Recent company filings

  1. 25-NSE - filed by NEW YORK STOCK EXCHANGE LLC regarding ALLURION TECHNOLOGIES, INC.Oct 13, 2026
  2. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory ArrangementsAug 24, 2026
  3. NT 10-Q filingAug 14, 2026
  4. Entry into a Material Definitive Agreement · Termination of a Material Definitive Agreement · Unregistered Sales of Equity SecuritiesJul 24, 2026
  5. 4 filingJul 23, 2026

Registered securities in this filing

Allurion Technologies, Inc. · 8-K · Filed 2026-01-12

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

Common stock, par value $0.0001 per share

Symbol
ALUR
Exchange
NYSE
Classification
COMMON
Filing context

Context: C_194a512c-1827-4d81-9218-d2ca06408a70

Dimensions: us-gaap:StatementClassOfStockAxis

Warrants to purchase 0.056818 shares of common stock, each at an exercise price of $202.50 per share of common stock

Symbol
ALUR WS
Exchange
NYSE
Classification
WARRANT
Filing context

Context: C_cab4c3ec-55bb-4669-a9f1-b7c5cffbd65a

Dimensions: us-gaap:StatementClassOfStockAxis

Accession 000119312526010462 · 2 registered-security cover members

Read the exact SEC filing ↗

Disclosure sections

Items 2.02, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 2.02Item 2.02 - Results of Operations
Item 2.02 Results of Operations and Financial Condition. On January 12, 2026, Allurion Technologies, Inc. issued a press release announcing selected preliminary financial results for the quarter and year ended December 31, 2025. The full text of that press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference. The information contained in this Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Filed exhibits (1)
EX-99.1 (by filename) alur-ex99_1.htm

Exhibit 99.1 Allurion Announces Preliminary Fourth Quarter and Full-Year 2025 Results Strong quarter-over-quarter revenue growth with continued, substantial improvement in operating expenses and operating loss NATICK, Mass. - January 12, 2026 - Allurion Technologies, Inc. (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced preliminary, unaudited results for the fourth quarter and full year 2025. Management expects preliminary, unaudited results for the period as follows: • Fourth quarter revenue of $3.3 million to $3.7 million, a 22% to 37% increase quarter-over-quarter, and full-year revenue of approximately $15 million • Substantial improvement in operating expenses and operating loss quarter-over-quarter and as compared to prior year “We are pleased with our results from the fourth quarter, where we grew revenue meaningfully quarter-over-quarter for the first time in more than one year as our new commercial strategy implemented after our strategic pivot in 2025 began to take hold,” said Dr. Shantanu Gaur, Founder and Chief Executive Officer. “We have also continued to reduce our operating losses through a sharpening of our strategic focus, and, wi…

Open exhibit ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.